--- title: PDO Screen – Patient-derived Organoids meet Cancer Modeling description: Learn how patient-derived organoids are revolutionizing oncology research by enabling accurate modeling of tumor biology, predicting drug response, and establishing biobanks for personalized medicine. Discover how this cutting-edge approach can help de-risk your drug development program. Book a free consultation with an expert today. image: https://blog.huborganoids.nl/hubfs/organoid-stained-dapi.png --- [![HUB Organoids](https://blog.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "HUB Organoids")](https://huborganoids.nl/) ![merk-m-logo-blue](https://blog.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png) - [services](https://huborganoids.nl/services) - [services overview](https://www.huborganoids.nl/services-overview/) - [drug screening](https://www.huborganoids.nl/services/hub-drug-screening/) - [model and assay development](https://www.huborganoids.nl/services/) - [clinical trials in a dish](https://www.huborganoids.nl/hub-organoid-clinical-trial-in-a-dish/) - [Technology](https://huborganoids.nl/hub-technology) - [Company](https://huborganoids.nl/about) - [about us](https://huborganoids.nl/about) - [Careers](https://huborganoids.nl/careers) - [events](https://www.huborganoids.nl/meet-us/) - [latest news](https://www.huborganoids.nl/news-insights-2/) - [Resources](https://huborganoids.nl/resources/) - [Blog](https://blog.huborganoids.nl) - [license program](https://www.huborganoids.nl/licenses/) - [Contact](https://resources.huborganoids.nl/contact-hub) [discover organoid services](https://www.huborganoids.nl/services-overview/) - [services](https://huborganoids.nl/services) - [services overview](https://www.huborganoids.nl/services-overview/) - [drug screening](https://www.huborganoids.nl/services/hub-drug-screening/) - [model and assay development](https://www.huborganoids.nl/services/) - [clinical trials in a dish](https://www.huborganoids.nl/hub-organoid-clinical-trial-in-a-dish/) - [Technology](https://huborganoids.nl/hub-technology) - [Company](https://huborganoids.nl/about) - [about us](https://huborganoids.nl/about) - [Careers](https://huborganoids.nl/careers) - [events](https://www.huborganoids.nl/meet-us/) - [latest news](https://www.huborganoids.nl/news-insights-2/) - [Resources](https://huborganoids.nl/resources/) - [Blog](https://blog.huborganoids.nl) - [license program](https://www.huborganoids.nl/licenses/) - [Contact](https://resources.huborganoids.nl/contact-hub) ## HUB's blog # PDO Screen – Patient-derived Organoids meet Cancer Modeling Published by HUB Organoids on Mar 21, 2023 PDO Screen – Patient-derived Organoids meet Cancer Modeling 4:44 ![PDO Screen – Patient-derived Organoids meet Cancer Modeling](https://blog.huborganoids.nl/hubfs/organoid-stained-dapi.png) ### Discover how patient-derived organoids can revolutionize oncology research by enabling accurate modeling of tumor biology and predicting patient response to treatment. We have come a long way in treating cancer. From surgeries, radiations, and injecting systemic drugs, to tailoring therapies that delicately disintegrate tumors. Despite advances in the field, there is still a considerable distance to go. The current statistics indicate that 95% of the anti-cancer agents that are developed in the preclinical phase falter as they progress toward clinical trials. ## The complexity of cancer biology Let’s be real. Cancer is an excruciatingly complex disease. Recent advances in genomics have demonstrated layers of genetic, transcriptomic, epigenetic, and /or phenotypic evidence that could make a cell cancerous[1](https://pubmed.ncbi.nlm.nih.gov/26528881/). The stochastic nature of the disease manifests in the form of both inter- and intra-tumor heterogeneity[2](https://pubmed.ncbi.nlm.nih.gov/22235286/),[3](https://pubmed.ncbi.nlm.nih.gov/29303512/). Inter-tumor heterogeneity refers to the existence of distinct mutational patterns in different tumors originating from the same patient, while intra-tumor heterogeneity refers to the coexistence of multiple cancer cell clones within a single tumor mass. Tumor heterogeneity especially contributes as a challenge in the early phase of drug development, where preclinical models with little to no patient relevance are used to identify, validate, and develop clinical candidates[3](https://pubmed.ncbi.nlm.nih.gov/29303512/). ## The lack of preclinical models that capture cancer biology While pre-clinical studies in conventional models such as cell lines and xenografts are a useful tool to screen compounds and provide useful biological insights, they do not show a good correlation with efficacy in Phase II trials or survival advantage in Phase III trials[4](https://pubmed.ncbi.nlm.nih.gov/11355958/) While cell lines are fast and easy to establish, they are markedly deficient in representing original tumor biology. While patient-derived xenografts and explants are better representatives of patient tumor antigen expression, they do not recapitulate the stromal component of the tumor, leaving open-ended questions on how the drug might respond in the tumor microenvironment. ## Mini tumors in the lab HUB Organoids derived from patient-derived tumor samples or biopsies reflect crucial features in terms of tumor architecture, genetic makeup, and the composition of differentiated cell types. Tumor organoids show a remarkable representation of interpatient tumor heterogeneity[5](https://europepmc.org/article/med/32694905) and have shown promising data in predicting patient drug response in the lab[6](https://resources.huborganoids.nl/elrig-2022-poster-patient-derived-organoids-predict-clinical-response). In a recent study[7](https://pubmed.ncbi.nlm.nih.gov/35469014/), HUB Organoids derived from colorectal cancer patients were used to develop the first bispecific against cancer stem cells in all solid tumor types. Remarkably, the bispecific was developed within five years, thanks to validating the therapeutic potential of the agent in a diverse panel of patient-derived organoids representative of the clinical setting. Patient-derived organoids established from single cells in tumor-adjacent normal crypts also allow testing for off-target and off-tumor toxicities within the same patients, making it easier to cross out compounds with toxic effects early in the drug development pipeline. ## Creating tumor organoid biobanks for personalized medicine Through years of experience, the culture conditions have undergone optimization and expansion, facilitating the establishment of organoid biobanks of a diverse range of solid tumor types, including intestine, colon, bladder, lung, liver, ovary, pancreas, kidney, breast, and stomach. Most biobanking studies confirm that patient-derived organoids (PDOs) reflect the characteristics of the primary tumor, at least at the level of bulk tumor DNA sequence[8](https://europepmc.org/article/pmc/4629330). Moreover, studies also show that the clonal drift over prolonged culture times for organoids is relatively small as compared to conventional models[9](https://pubmed.ncbi.nlm.nih.gov/27212702/),[10](https://pubmed.ncbi.nlm.nih.gov/31011202/). Retrospective studies have indicated that the response of PDO to therapies closely resembles the initial response of patients to the same treatments[11](https://pubmed.ncbi.nlm.nih.gov/30213835/). Beyond the empiric potential of PDOs to help choose therapies for individual patients, large panels of PDOs representing one type of cancer have been used to develop biomarkers predictive of drug response[12](https://pubmed.ncbi.nlm.nih.gov/29625057/). The evolution of organoid modeling is happening at an unprecedented pace, and the potential for this cutting-edge approach to revolutionize oncology and advance clinical research is truly exciting. Want to know how patient-derived organoids can help you de-risk your drug development program? Book a [free consultation](https://resources.huborganoids.nl/contact-hub) with an expert. Tags: [organoid technology](https://blog.huborganoids.nl/tag/organoid-technology) ### Subscribe to our blog ### Related blogs ![Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?](https://blog.huborganoids.nl/hubfs/ask-the-expert-yasmine-1.jpg) ### [Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?](https://blog.huborganoids.nl/ask-the-expert-how-can-patient-derived-organoids-accelerate-kras-drug-development) Published by HUB Organoids on Jul 5, 2024 In this edition of Ask the Expert, featuring Dr. Yasmine Abouleila, we explore the transformative potential of ... [read more](https://blog.huborganoids.nl/ask-the-expert-how-can-patient-derived-organoids-accelerate-kras-drug-development) ![Decoding adult stem cells: exploring the hallmarks of stemness](https://blog.huborganoids.nl/hubfs/SocialMedia-Blog-decoding-adult-stem-cells%20(1).jpg) ### [Decoding adult stem cells: exploring the hallmarks of stemness](https://blog.huborganoids.nl/the-six-hallmarks-of-adult-stem-cells) Published by HUB Organoids on Feb 19, 2024 Discover the 6 hallmarks of stemness in adult tissue Mammalian organ systems face a constant barrage of internal and ... [read more](https://blog.huborganoids.nl/the-six-hallmarks-of-adult-stem-cells) ![Ask the Experts – organoid & immune cell co-cultures for immunotherapy](https://blog.huborganoids.nl/hubfs/Ask%20the%20Expert-linkedin-blog%20image%20(1).jpg) ### [Ask the Experts – organoid & immune cell co-cultures for immunotherapy](https://blog.huborganoids.nl/ask-the-experts-organoid-and-immune-cell-co-cultures-for-immunotherapy) Published by HUB Organoids on Jun 23, 2023 In this post of our "Ask the Experts" series, we provide comprehensive answers to frequently asked questions regarding ... [read more](https://blog.huborganoids.nl/ask-the-experts-organoid-and-immune-cell-co-cultures-for-immunotherapy) ![HUB Organoids](https://blog.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "HUB Organoids") [Privacy Policy](https://huborganoids.nl/privacy-policy) HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany ***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.*